Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study

Angelo Bertani, G. Perna, G. Migliarese, D. Di Pasquale, M. Cucchi, D. Caldirola, L. Bellodi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Introduction: Serotonergic agents have greater effectiveness than noradrenergic ones in the treatment of Panic Disorder (PD). However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD. Methods: Sixty-eight patients with PD were assigned to treatment groups in a single-blind, randomized design. Each patient was assessed at day 0 and 90 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Side effects were also recorded. Results: Reduction of PASS scores was significantly greater in the paroxetine group than in the reboxetine one. Vice versa we did not find any significant differences for other outcome measures. Sexual dysfunction and weight gain were significantly less frequent in the reboxetine group. Conclusions: The results showed a greater effect of paroxetine on panic attacks than reboxetine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD.

Original languageEnglish
Pages (from-to)206-210
Number of pages5
JournalPharmacopsychiatry
Volume37
Issue number5
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Single-Blind Method
Paroxetine
Panic Disorder
Panic
Therapeutics
Serotonin Agents
Weight Gain
Fear
reboxetine
Serotonin
Norepinephrine
Anxiety
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bertani, A., Perna, G., Migliarese, G., Di Pasquale, D., Cucchi, M., Caldirola, D., & Bellodi, L. (2004). Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study. Pharmacopsychiatry, 37(5), 206-210. https://doi.org/10.1055/s-2004-832593

Comparison of the treatment with paroxetine and reboxetine in panic disorder : A randomized, single-blind study. / Bertani, Angelo; Perna, G.; Migliarese, G.; Di Pasquale, D.; Cucchi, M.; Caldirola, D.; Bellodi, L.

In: Pharmacopsychiatry, Vol. 37, No. 5, 09.2004, p. 206-210.

Research output: Contribution to journalArticle

Bertani, A, Perna, G, Migliarese, G, Di Pasquale, D, Cucchi, M, Caldirola, D & Bellodi, L 2004, 'Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study', Pharmacopsychiatry, vol. 37, no. 5, pp. 206-210. https://doi.org/10.1055/s-2004-832593
Bertani, Angelo ; Perna, G. ; Migliarese, G. ; Di Pasquale, D. ; Cucchi, M. ; Caldirola, D. ; Bellodi, L. / Comparison of the treatment with paroxetine and reboxetine in panic disorder : A randomized, single-blind study. In: Pharmacopsychiatry. 2004 ; Vol. 37, No. 5. pp. 206-210.
@article{e927fe26945d454db92a6014a7d58f9b,
title = "Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study",
abstract = "Introduction: Serotonergic agents have greater effectiveness than noradrenergic ones in the treatment of Panic Disorder (PD). However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD. Methods: Sixty-eight patients with PD were assigned to treatment groups in a single-blind, randomized design. Each patient was assessed at day 0 and 90 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Side effects were also recorded. Results: Reduction of PASS scores was significantly greater in the paroxetine group than in the reboxetine one. Vice versa we did not find any significant differences for other outcome measures. Sexual dysfunction and weight gain were significantly less frequent in the reboxetine group. Conclusions: The results showed a greater effect of paroxetine on panic attacks than reboxetine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD.",
author = "Angelo Bertani and G. Perna and G. Migliarese and {Di Pasquale}, D. and M. Cucchi and D. Caldirola and L. Bellodi",
year = "2004",
month = "9",
doi = "10.1055/s-2004-832593",
language = "English",
volume = "37",
pages = "206--210",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - Comparison of the treatment with paroxetine and reboxetine in panic disorder

T2 - A randomized, single-blind study

AU - Bertani, Angelo

AU - Perna, G.

AU - Migliarese, G.

AU - Di Pasquale, D.

AU - Cucchi, M.

AU - Caldirola, D.

AU - Bellodi, L.

PY - 2004/9

Y1 - 2004/9

N2 - Introduction: Serotonergic agents have greater effectiveness than noradrenergic ones in the treatment of Panic Disorder (PD). However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD. Methods: Sixty-eight patients with PD were assigned to treatment groups in a single-blind, randomized design. Each patient was assessed at day 0 and 90 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Side effects were also recorded. Results: Reduction of PASS scores was significantly greater in the paroxetine group than in the reboxetine one. Vice versa we did not find any significant differences for other outcome measures. Sexual dysfunction and weight gain were significantly less frequent in the reboxetine group. Conclusions: The results showed a greater effect of paroxetine on panic attacks than reboxetine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD.

AB - Introduction: Serotonergic agents have greater effectiveness than noradrenergic ones in the treatment of Panic Disorder (PD). However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD. Methods: Sixty-eight patients with PD were assigned to treatment groups in a single-blind, randomized design. Each patient was assessed at day 0 and 90 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Side effects were also recorded. Results: Reduction of PASS scores was significantly greater in the paroxetine group than in the reboxetine one. Vice versa we did not find any significant differences for other outcome measures. Sexual dysfunction and weight gain were significantly less frequent in the reboxetine group. Conclusions: The results showed a greater effect of paroxetine on panic attacks than reboxetine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD.

UR - http://www.scopus.com/inward/record.url?scp=4644307179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644307179&partnerID=8YFLogxK

U2 - 10.1055/s-2004-832593

DO - 10.1055/s-2004-832593

M3 - Article

C2 - 15359375

AN - SCOPUS:4644307179

VL - 37

SP - 206

EP - 210

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 5

ER -